Cibus, Inc. - Class A Common Stock (CBUS)

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced the closing of its previously announced public offering of 15,714,285 shares of its Class A Common Stock, at a purchase price of $1.75 per share, including to institutional and strategic investors, as well as the Chairman of Cibus’ board of directors (5,714,286 shares).

This action follows the USDA’s recent designation of Cibus’ disease resistance traits in Canola as not regulated, continuing Cibus’ product development momentum in the globally important Canola crop

SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced the pricing of its previously announced public offering of 15,714,285 shares of its Class A Common Stock, at a purchase price of $1.75 per share, including to institutional and strategic investors, as well as the Chairman of Cibus’ board of directors (5,714,286 shares).

SAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that it intends to offer shares of its Class A common stock (or common stock equivalents in lieu thereof) in a public offering. All of the securities to be sold in the offering are to be offered by Cibus. The Chairman of Cibus’ board of directors, Mr. Rory Riggs, has indicated an interest in purchasing up to $10.0 million of shares of Class A common stock and/or common stock equivalents in this offering. Because such an indication of interest is not a binding agreement or commitment to purchase, Mr. Riggs may elect not to purchase any shares in this offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Peter Beetham, Co-Founder, President and Interim Chief Executive Officer, participated in the BofA Securities 2025 AgTech Virtual Conference this week.

SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Peter Beetham, Co-Founder, President, and Interim Chief Executive Officer, will host a presentation at the AGP Annual Virtual Healthcare Company Showcase.

Rice business momentum builds with Cibus' first stacked gene edited herbicide tolerance traits, which the Company believes is an industry first; On track for 2027 targeted commercial launch of HT1 and HT3 traits with customer germplasm integration underway across multiple markets

Designation confirms conventional regulation of Cibus herbicide tolerance traits in Rice in Ecuador paving the way for further product development and eventual commercialization in a key Rice growing region

SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2025 financial results on Thursday, May 8, 2025. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.

Designation confirms conventional regulation of Cibus traits in the U.S. as modernized regulatory policy for precision gene editing breeding technologies continues to advance globally

A major milestone on March 14th 2025 advanced the EU Trilogue discussions aimed to complete the final text of the New Genomic Techniques (NGTs) or gene editing legislation for the EU; California Rice Commission approved Cibus' field research proposal marking the first time gene edited Rice has been authorized for planting within the state

Legislation aims to adapt EU law to reflect scientific and technological progress, enabling the products of New Genomic Techniques (NGTs), such as gene editing, to contribute to more sustainable agriculture, climate resilience, and food security

SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report fourth quarter 2024 financial results on Thursday, March 20, 2025. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.

Initial bioassay data for Cibus’ third mode of action for white mold (Sclerotinia) resistance trait in canola shows promising results in controlled environment assessment

SAN DIEGO, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced key leadership changes pursuant to the Company’s succession planning strategy. The Board has accepted Rory Riggs’ resignation as the Company’s Chief Executive Officer. Peter Beetham, the Company’s President and Chief Operating Officer, also will serve as the Company’s Interim Chief Executive Officer. Dr. Beetham is a co-founder of Cibus Global with Mr. Riggs and with Greg Gocal, who will remain the Company’s Chief Scientific Officer. Mr. Riggs will remain Chairman of the Board of Directors. Dr. Beetham also will continue as a director.

SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today issued a correction relating to the rice conversion rates previously disclosed in its January 16, 2025 press release. The Company has concluded that the gene editing conversion rates of 10-25% in Rice have not been reconfirmed based upon subsequent experiments and high variability in the conversion rate data. Cibus is continuing to advance its oligonucleotide directed mutagenesis (ODM) editing technologies to drive improved editing conversion rates across its developed traits across its crops of interest.

SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, and Peter Beetham, Co-Founder, President, and Chief Operating Officer, will host a presentation at the Sidoti Micro Cap Conference.

NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 22-23, 2025. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.

SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced it has entered into securities purchase agreements with existing investors of the Company, including institutional and strategic investors, as well as with the Company’s CEO, Rory Riggs, for the purchase and sale of 9,040,000 shares of its Class A Common Stock (inclusive of pre-funded warrants to purchase shares of Class A Common Stock, in lieu of common stock), and warrants to purchase up to an aggregate of 9,040,000 shares of Class A Common Stock, at a combined purchase price per share (and accompanying warrant) of $2.50 per share ($2.4999 in respect of the pre-funded warrants (and accompanying warrant)), pursuant to a registered direct offering priced above Nasdaq’s Minimum Price in accordance with Nasdaq rules. The warrants will be exercisable upon stockholder approval at a price of $2.50 per share, and will expire five years following the date of stockholder approval. Following stockholder approval, the warrants will be redeemable, at the Company’s option, at a redemption price of $0.0001 per warrant following the satisfaction of certain conditions, including (i) the Company’s announcement of an operational soybean platform and (ii) the closing price of the Class A Common Stock equaling or exceeding $5.00 per share for fifteen consecutive trading days.

Culmination of Advances in Gene Editing Efficiency and Process Improvements Drives Standardization of Cibus’ Gene Editing System Delivering Traits in a Customer’s Elite Germplasm in less than 12 Months

Cibus’ Rice Herbicide Tolerance (HT-3) Commercialization Efforts Continue Promising Progress to deliver a new Weed Management Solution for Farmers in the U.S.

Cibus and Biographica to collaborate on identifying gene editing targets for Cibus’ disease resistance trait development

SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, will participate in the 13th Annual Roth Technology Conference.

Cibus has successfully made the edits in Canola associated with the Company’s 4th mode of action for its White Mold (Sclerotinia) trait

Announced a strategic realignment to advance commercial opportunities, focusing resources on advancement of weed management platform (HT1 and HT3) for Rice, Pod Shatter Reduction in Canola, Sclerotinia resistance for Canola and Soybean, and on Soybean platform development